Krónikus mieloid leukémia (CML): ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• ABL1 12
• TP53 1
• JAK 1
• AKT 0
• IDH 4
• ERK 0
• FLT3 2
• PI3K 0
• JNK 0
• STAT3 0
• BCL-2 2
• CD19 1
• HSP90 0
• KIT 1
• PDGFR 0
• CSF1R 2
• HDAC 0
• HIF-1 0
• IL-1 2
• MAPK 0
• PPAR 0
• AMPK 0
• CD123 0
• CD38 1
• CTNNB1 0
• EGFR 0
• FGFR 0
• mTOR 0
• NLRP3 0
• NRF2 0
• RAS 0
• RUNX1 0
• BTK 0
• CD20 0
• CD22 0
• CD33 0
• CD40 0
• CD47 1
• CTLA-4 0
• CXCR4 0
• G6PD 0
• GLP-1 0
• IL-15 0
• IL-6 1
• KRAS 0
• MEK 1
• MYC 0
• NPM1 0
• NRAS 0
• PD-1 0
• PRMT5 0
• PTEN 0
• SGLT2 0
• SIRT1 0
• TIM-3 0
• YAP 0

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon 2020) · ERC-STG

  Functional Interrogation of Non-coding DNA Sequences in leukemia development and drug resistance (FIND-seq)

  St. Anna Kinderkrebsforschung Gmbh· Wien, Ausztria· EU contribution 1 784 000 EUR· until 2027. aug.

  The disease is named only in the funder's project summary, not in the title.

1 of 1 running projects, newest first. Listed amounts together: 1,8 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Leállították

  Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)

  NCT04266301· Novartis Pharmaceuticals· Frissítve: 2026. jan. 13.

  “In December 2023, Novartis decided to terminate the sabatolimab clinical development program early after Phase II (MDS1) and Phase III (MDS2) studies failed to meet their primary objectives. The termination was not due to safety concerns.”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)

  NCT04266301· Novartis Pharmaceuticals· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 4
• Mendelian Randomization Analysis 3
• CRISPR-Cas Systems 2
• Gene Expression Profiling 6
• Sequence Analysis, RNA 2
• Exome Sequencing 1
• Proteomics 5
• Metabolomics 3
• Mass Spectrometry 2
• Flow Cytometry 13
• Xenograft Model Antitumor Assays 19
• Magnetic Resonance Imaging 4
• Machine Learning 3
• Cohort Studies 9
• Genome-Wide Association Study 3

• Extramedullary T-Lymphoblastic Blast Crisis in Chronic Myeloid Leukaemia: A Unique Cytologic Diagnosis Confirmed by Flow Cytometry.

  Cytopathology, 2026. szept.

• Peripheral Blood Profiles Reflecting Progenitor Lineage Balance are Associated With Molecular Response in Chronic Myeloid Leukemia.

  Exp Hematol, 2026. aug.

• What is the optimal threshold for aberrant lymphoblasts at diagnosis to predict lymphoid transformation in chronic myeloid leukemia?

  Cytometry B Clin Cytom, 2026. jún.

• Simultaneous chromatographic quantification of upadacitinib, nilotinib, and tryptophan decoding myeloid leukemia and liver cancer integrated with ELISA and Flow cytometry.

  J Chromatogr B Analyt Technol Biomed Life Sci, 2025. dec.

• Chemopreventive Effects of Dietary Eicosapentaenoic Acid Supplementation in Experimental Myeloid Leukemia.

  Cancer Prev Res (Phila), 2015. aug.

• Coformulation of doxorubicin and curcumin in poly(D,L-lactide-co-glycolide) nanoparticles suppresses the development of multidrug resistance in K562 cells.

  Mol Pharm, 2011. ápr.

• Curcumin stimulates reactive oxygen species production and potentiates apoptosis induction by the antitumor drugs arsenic trioxide and lonidamine in human myeloid leukemia cell lines.

  J Pharmacol Exp Ther, 2010. júl.

• [Reactive oxygen species and mitochondrial membrane potential changes in leukemia cells during 6-gingerol induced apoptosis].

  Zhong Yao Cai, 2010. ápr.

• Combination of simvastatin and imatinib sensitizes the CD34+ cells in K562 to cell death.

  Med Oncol, 2010. márc.

• [Effect of berberine on the differentiation and apoptosis of K562 cell line].

  Zhong Yao Cai, 2009. márc.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.